Appointment of Non-Executive Director
Updated : 07:07
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
Appointment of Non-Executive Director
Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that Richard Bungay will join the Board as a Non-Executive Director with immediate effect.
Mr. Bungay has over 25 years' experience in corporate roles with R&D-based companies within the biotechnology and pharmaceutical sector, including as CFO of both public and private companies, with a particular focus on financing, investor relations and business development. Richard is currently CFO of Diurnal Group plc, the AIM quoted specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases.
Prior to that, Richard was CFO and Chief Operating Officer of Mereo BioPharma Group plc, a biopharmaceutical company focused on rare and specialty diseases. Richard's other experience includes being CFO of Glide Technologies, a device and development company focused on solid dose formulations of therapeutics and vaccines, and CFO of Verona Pharma plc, a drug development company focused on first-in-class medicines to treat respiratory diseases.
Richard qualified as a Chartered Accountant with Deloitte in 1993.
The following information regarding the appointment of Richard Edward Bungay (aged 51) is required to be disclosed under Schedule 2(g) of the AIM Rules for Companies:
Current directorships and/or partnerships | Former directorships and/or partnerships |
Chroma Therapeutics Limited | Glide Pharmaceutical Technologies Limited |
Diurnal Group plc | Mereo Biopharma Group plc |
The Forest School Academy Trust | |
There are no further disclosures to be made under Schedule 2(g) of the AIM Rules for Companies.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014
Enquiries
Cambridge Cognition Holdings PLC | |
Matthew Stork, Chief Executive Officer Nick Walters, Chief Financial Officer | Tel: 01223 810 700 |
finnCap Ltd (NOMAD and Joint Broker) | Tel: 020 7220 0500 |
Geoff Nash / Simon Hicks | (Corporate Finance) |
Alice Lane / Manasa Patil | (Corporate Broking)
|
Dowgate Capital Limited (Joint Broker) David Poutney/ James Serjeant | Tel: 020 3903 7715 (Corporate Broking) |
IFC Advisory Limited (Financial PR and IR) | Tel: 020 3934 6630 |
Tim Metcalfe/ Graham Herring/ Zach Cohen |
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The Company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.